San Francisco: German pharmaceutical giant Merck and a US partner reported promising results Saturday in trials of a drug administered orally to fight COVID-19, saying it helps reduce patients' viral load. "At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data," said Wendy Painter, chief medical officer of the US firm, Ridgeback Biotherapeutics. In January, Merck halted work on two COVID vaccine candidates but has pressed on with research into two products to treat the disease, including a pill-based one called molnupiravir, which it has developed with Ridgeback Biotherapeutics. This drug caused a significant drop in pat
Hence then, the article about oral covid 19 treatment yields promising trial data drugmakers was published today ( ) and is available onGulf News ( United Arab Emirates ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Oral COVID-19 treatment yields promising trial data: Drugmakers )